Latest News
“At the end of the day, I think the important information here is that there’s a durability of response,” said Nowak. “Not only did patients get better in the initial study period, but they continued to remain better, and maybe improve further, the longer they were on the medication.”
- September 14, 2026Source: MSN Health & Fitness (with Richard Nowak, MD)
You need to listen to your body in terms of how much activity you aim to do, but once your condition starts to stabilize, regular exercise is important, says Richard Nowak, MD, an associate professor of neurology and the director of the Yale myasthenia gravis clinic in New Haven, Connecticut.
- July 01, 2026
A Q&A with Alexandra Bayer Wildberger, PhD, a postdoctoral associate in the lab of Kevin O’Connor, PhD, who was selected to receive a 2026 American Brain Foundation Next Generation Research Grant in the area of myasthenia gravis for her project, “Investigating the Role of the Immune System’s First Responders in Myasthenia Gravis.”
- November 03, 2025Source: HCPLive
Autoreactive B-cells contribute to the onset and progression of generalized myasthenia gravis (gMG) through their role in autoantibody production. Targeting these cells, monoclonal antibody inebilizumab (Uplizna; Amgen), an FDA-approved treatment for neuromyelitis optica spectrum disorder, is currently being investigated in the phase 3 MINT trial (NCT04524273) as a potential therapy for patients with gMG.
- May 19, 2025Source: WTNH News8
Huned Patwa, MD, chief, division of neuromuscular medicine, and professor of neurology, outlines the symptoms of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's Disease, as well as the latest research and treatments into the neurodegenerative disease.
- November 17, 2023Source: Yale Medicine
There has been encouraging progress in treatments for myasthenia gravis, an autoimmune condition that causes muscle weakness. Yale experts discuss these new options.
- November 06, 2023Source: Medpage Today
Major advances in treatment options have been game-changers for people diagnosed with myasthenia gravis (MG). Experts comment on current MG treatment methods, as well as exciting new research.
- November 03, 2023Source: Medpage Today
Following a wave of new approvals in recent years, adults with generalized myasthenia gravis (gMG) now have a wider variety of treatment options to manage their symptoms.
- April 12, 2023
The Myasthenia Gravis Foundation of America (MGFA) has awarded its Impact Award to Richard Nowak, MD for his exceptional leadership, collaboration, innovation, and dedication to advancing the mission of the MGFA. Dr. Nowak was formally recognized at the 2023 MGFA National Patient Conference in New Orleans, La.
- February 06, 2023Source: NeurologyLive
the Myasthenia Gravis Foundation of America (MGFA) partnered with Alira Health to re-launch its MGFA Global MG Patient Registry. Yale assistant professor Richard Nowak, MD, MGFA’s chief medical advisor, discusses the importance of this registry, which allows MG patients to report their symptoms on a secure platform and informs future clinical trials and advances in treatment.